Comparative Pharmacology
Head-to-head clinical analysis: ACEON versus ENALAPRIL MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACEON versus ENALAPRIL MALEATE.
ACEON vs ENALAPRIL MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACEON (perindopril) is an angiotensin-converting enzyme (ACE) inhibitor. It inhibits ACE, which converts angiotensin I to angiotensin II, a potent vasoconstrictor. This results in decreased vasopressor activity, reduced aldosterone secretion, and lower peripheral vascular resistance, leading to antihypertensive effects.
Enalapril is a prodrug that is hydrolyzed to enalaprilat, a potent competitive inhibitor of angiotensin-converting enzyme (ACE), blocking the conversion of angiotensin I to angiotensin II, reducing vasoconstriction, aldosterone secretion, and sodium/water retention.
Initial: 4 mg orally once daily; titrate to 8-32 mg daily in 1-2 divided doses. Typical maintenance: 8-16 mg daily.
Initial: 5 mg orally once daily; titrate to 10-40 mg/day in 1-2 divided doses. Target: 10-40 mg/day. Maximum: 40 mg/day. Route: Oral. Frequency: Once or twice daily.
None Documented
None Documented
Perindoprilat: terminal half-life ~30 hours (up to 120 hours in elderly or heart failure due to prolonged terminal phase from slow dissociation from ACE binding); perindopril: ~1.5 hours.
Terminal elimination half-life of enalaprilat (active metabolite) is approximately 35-38 hours. This prolonged half-life supports once-daily dosing in most patients, but may require dosage adjustment in renal impairment.
Renal: approximately 30% as perindopril and 20% as perindoprilat; fecal: approximately 50% as metabolites.
Primarily renal (60-80% as unchanged drug and metabolites, mainly enalaprilat); biliary/fecal excretion accounts for the remainder (approximately 20-30%).
Category C
Category D/X
ACE Inhibitor
ACE Inhibitor